Market Access Verona to take COPD hopeful into phase 3 Verona Pharma is to take lung drug RPL554 into late clinical development after a successful phase 2b trial.
News AZ boosted by COPD triple inhaler results AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success.
News Rumours of $1.65bn GSK bid for respiratory partners Vectura GlaxoSmithKline could be poised to acquire its respiratory partner, UK biotech Vectura, for $1.65bn.
News Sunovion's COPD nebuliser approved in US Device aims to help patients get a full dose of medication
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
